Mitochondrial Decline, Aging, and Peptides

Mitochondrial-Derived Peptides

8 weeks to reverse

Eight weeks of SS-31 (elamipretide) treatment reversed age-related cardiac dysfunction and mitochondrial protein damage in old mice.

Whitson et al., GeroScience, 2021

Whitson et al., GeroScience, 2021

View as image

Every cell in your body contains hundreds to thousands of mitochondria, and every one of them works worse as you age. By your 70s, mitochondrial ATP production has dropped by 30-50% compared to your 30s. This is not a minor detail of aging. Mitochondrial dysfunction drives muscle weakness, cardiac decline, neurodegeneration, insulin resistance, and the chronic low-grade inflammation that characterizes old age.^[1] Three classes of peptides have emerged as potential tools to intervene: mitochondrial-derived peptides (MDPs) like MOTS-c and humanin that your own mitochondria produce, and synthetic mitochondria-targeted peptides like SS-31 (elamipretide) that are engineered to reach the inner mitochondrial membrane. For background on the broader family of these molecules, see the pillar article on humanin, the cytoprotective peptide from your mitochondria. This article covers how mitochondrial decline drives aging and what each of these peptides does about it.

What goes wrong with mitochondria as you age

Mitochondrial decline is not a single event. It is a cascade of interconnected failures that accelerate each other.

Electron transport chain dysfunction. The four protein complexes of the electron transport chain lose efficiency with age. Electrons that should flow smoothly to produce ATP instead leak out and react with oxygen to form reactive oxygen species (ROS). This creates a feedback loop: ROS damage the very proteins and lipids that make up the electron transport chain, which causes more electron leakage, which produces more ROS.^[2]

Mitochondrial DNA mutations. Unlike nuclear DNA, mitochondrial DNA (mtDNA) has limited repair mechanisms and sits directly next to the ROS-generating electron transport chain. Over decades, mtDNA accumulates mutations that further compromise the proteins it encodes. Since mtDNA encodes 13 essential subunits of the electron transport chain, even a few mutations can degrade ATP production.

Cardiolipin oxidation. Cardiolipin is a phospholipid found almost exclusively in the inner mitochondrial membrane. It anchors the electron transport chain complexes into functional supercomplexes. With age, cardiolipin becomes oxidized by ROS, disrupting supercomplex organization and further reducing electron transport efficiency. This is the specific target that SS-31 addresses.^[3]

Declining quality control. Healthy cells remove damaged mitochondria through a process called mitophagy and replace them with new ones through mitochondrial biogenesis. Both processes slow with age, allowing damaged mitochondria to accumulate rather than being recycled.

Reduced signaling peptide production. Mitochondria produce their own signaling peptides, encoded in the mitochondrial genome. As mitochondrial function declines, production of these peptides drops. Since several of these peptides (MOTS-c, humanin) have protective and regulatory functions throughout the body, their decline removes a layer of metabolic defense at the time it is most needed.

MOTS-c: the exercise-mimetic peptide that declines with age

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a 16-amino-acid peptide encoded in the mitochondrial genome. Lee and colleagues discovered it in 2015, showing that MOTS-c promotes metabolic homeostasis, reduces obesity, and improves insulin sensitivity in mice.^[4] The discovery was striking because it demonstrated that mitochondria are not just energy producers; they are endocrine organs that send signals to the rest of the body.

MOTS-c's mechanism centers on AMPK activation. When cells are under metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus, where it directly regulates gene expression related to inflammation, cellular repair, and stress resilience.^[5] Kim and colleagues showed in 2018 that this nuclear translocation is triggered by metabolic stress, connecting mitochondrial state to nuclear gene regulation in a way that was previously unknown.

The aging connection became clearer through several studies. Reynolds and colleagues demonstrated in 2021 that MOTS-c functions as an exercise-induced mitochondrial regulator of age-dependent physical decline. In old mice, MOTS-c treatment improved physical capacity, skeletal muscle homeostasis, and metabolic function.^[6] D'Souza and colleagues found that in healthy aging men, higher skeletal muscle expression of MOTS-c correlated with better muscle fiber composition, suggesting it plays a role in maintaining muscle quality during aging.^[7]

But circulating MOTS-c levels decline with age. Cobb and colleagues measured MDPs across age groups in 2016 and found that both MOTS-c and humanin decrease as people get older. The decline correlated with increasing insulin resistance and inflammatory markers.^[1] This creates a paradox: the peptide that could help mitigate aging-related metabolic decline becomes less available precisely when it is needed. For more on this trajectory, see the dedicated article on why MOTS-c declines with age.

Mohtashami and colleagues reviewed the full landscape of MOTS-c research in aging and age-related diseases in 2022, noting its effects on glucose metabolism, inflammation, and cellular senescence.^[8] The breadth of MOTS-c's effects across multiple aging-related pathways has generated interest in whether exogenous MOTS-c administration could serve as a therapeutic intervention, though human clinical trial data remains absent.

Humanin: the cytoprotective peptide that protects aging tissues

Humanin is a 24-amino-acid peptide also encoded in the mitochondrial genome. It was originally discovered in 2001 as a neuroprotective factor against Alzheimer's disease, but subsequent research revealed protective effects across multiple organ systems.

Qin and colleagues tested chronic humanin treatment in aging mice in 2018. Mice receiving humanin from middle age onward showed reduced age-related myocardial fibrosis, the scarring of heart tissue that progressively stiffens the heart with age.^[9] This finding is relevant because cardiac fibrosis is a major driver of diastolic heart failure in the elderly, a condition with limited treatment options.

Karachaliou and Livaniou reviewed the neuroprotective evidence for humanin and its analogs in 2023, documenting effects against amyloid-beta toxicity, oxidative stress, and neuronal apoptosis in preclinical models.^[10] Humanin analogs (HNG, [Gly14]-Humanin) have been engineered with increased potency and stability compared to native humanin. For the full picture on humanin's biology, the pillar article on humanin covers its mechanisms in detail.

Like MOTS-c, humanin declines with age. The Cobb 2016 study showed this decline tracks with deteriorating metabolic health markers.^[1] The pattern is consistent: as mitochondrial function degrades, the protective peptides mitochondria produce become less abundant, removing a biological buffer against aging.

SS-31 (elamipretide): synthetic rescue of mitochondrial function

Unlike MOTS-c and humanin, which are naturally produced by mitochondria, SS-31 is a synthetic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) designed to penetrate cells and concentrate in the inner mitochondrial membrane, where it binds cardiolipin.

The aging data is among the most compelling in the mitochondrial peptide space. Sweetwyne and colleagues showed in 2017 that SS-31 improved glomerular architecture in aged mice, reversing kidney aging at the structural level.^[3] Whitson and colleagues demonstrated in 2021 that 8 weeks of elamipretide treatment almost completely reversed age-related increases in S-glutathionylation (a form of oxidative protein damage) in mouse hearts.^[11]

At the mechanistic level, Pharaoh and colleagues showed in 2023 that elamipretide improves ADP sensitivity in aged mitochondria by enhancing uptake through the adenine nucleotide translocator (ANT).^[12] In simpler terms: old mitochondria lose their ability to efficiently convert ADP back to ATP, and SS-31 partially restores this ability by improving the transport mechanism.

SS-31 went further into clinical development than any other mitochondria-targeted peptide. Stealth BioTherapeutics (now renamed) advanced elamipretide into clinical trials for Barth syndrome (a genetic mitochondrial disorder), heart failure with preserved ejection fraction, and primary mitochondrial myopathy. The results were mixed: some trials showed improvements in specific endpoints, but the pivotal heart failure trials did not meet their primary endpoints. This does not invalidate the preclinical aging data, but it highlights the gap between reversing mitochondrial dysfunction in aged mice and producing measurable clinical improvement in human disease trials.

How these peptides work together

These three peptides operate at different levels of the mitochondrial aging problem:

MOTS-c functions as a systemic metabolic regulator. It does not directly fix mitochondria; instead, it activates AMPK and adjusts nuclear gene expression to improve metabolic fitness body-wide. Its effects mirror exercise: improved insulin sensitivity, reduced fat accumulation, and enhanced muscle homeostasis. This aligns with the research on MOTS-c and physical performance.

Humanin acts as a cytoprotective agent. It blocks apoptotic pathways, reduces oxidative stress, and prevents tissue fibrosis. Its primary value in aging appears to be protecting vulnerable tissues (brain, heart) from damage accumulation.

SS-31 targets the inner mitochondrial membrane directly. By stabilizing cardiolipin and restoring electron transport chain efficiency, it addresses the root cause of mitochondrial ROS production. It is the most mechanistically direct of the three.

Whether combining these approaches produces additive benefits is unstudied. The logical framework suggests it could: SS-31 restoring mitochondrial membrane function, MOTS-c improving systemic metabolic regulation, and humanin protecting tissues from damage already in progress. But no combination study has been conducted.

The gap between preclinical promise and human evidence

The mitochondrial peptide field has a consistent pattern: strong preclinical data and limited human evidence.

No human aging trials exist. All aging-related data for MOTS-c, humanin, and SS-31 comes from cell culture, animal models, or observational human studies. No randomized controlled trial has tested whether any of these peptides slow or reverse aging processes in humans.

Animal model limitations. Mouse studies dominate the field. Mice age differently than humans in important ways: their mitochondrial mutation rates differ, their antioxidant systems are configured differently, and their lifespans compress decades of human mitochondrial decline into months. Interventions that reverse mitochondrial dysfunction in 24-month-old mice may not translate to 70-year-old humans.

SS-31's clinical disappointments. The failure of elamipretide in pivotal heart failure trials suggests that even a well-characterized mitochondria-targeted peptide may not produce clinically meaningful improvements in complex human disease, at least not with the dosing and duration tested.

MOTS-c dose and delivery questions. The exercise-mimetic effects of MOTS-c in mice used systemic injection. How much MOTS-c would be needed in humans, how often, and by what route remains unknown. The peptide's stability and half-life in human circulation have not been characterized in published clinical studies.

Humanin is still preclinical. Despite two decades of research since its discovery, humanin has not entered clinical trials for any age-related indication. The analogs HNG and [Gly14]-Humanin exist as research tools, not pharmaceutical candidates.

These gaps should not be confused with negative evidence. The biological rationale connecting mitochondrial decline to aging is well-established, and the peptide data in animals is consistent and reproducible across multiple independent labs. The question is not whether mitochondrial decline drives aging; it is whether peptide interventions can meaningfully reverse it in humans. That question awaits clinical trials. For related research on how other longevity-focused peptide pathways intersect with mitochondrial biology, see the article on NAD+ and peptide longevity pathways.

The Bottom Line

Mitochondrial dysfunction is a central driver of aging, producing cascading failures in energy production, protein quality, and tissue homeostasis. Three classes of peptides target different aspects of this decline: MOTS-c improves systemic metabolism as an exercise mimetic, humanin protects tissues from apoptosis and fibrosis, and SS-31 directly restores inner mitochondrial membrane function. All three show consistent benefits in animal models of aging. Circulating levels of MOTS-c and humanin decline naturally with age, suggesting their loss contributes to age-related deterioration. No human aging trial has tested any of these peptides, and SS-31's mixed clinical results in human disease trials highlight the gap between preclinical promise and therapeutic reality.

Frequently Asked Questions

What are mitochondrial-derived peptides?

Mitochondrial-derived peptides (MDPs) are small signaling molecules encoded in the mitochondrial genome. At least 13 have been identified, including MOTS-c and humanin. Unlike nuclear-encoded proteins, these peptides originate from mitochondrial DNA and function as retrograde signals, communicating mitochondrial status to the rest of the cell and body to regulate metabolism, stress responses, and cell survival.

Does MOTS-c really mimic exercise?

In mouse studies, MOTS-c activates AMPK (the same energy sensor activated by exercise), improves insulin sensitivity, reduces fat mass, and enhances skeletal muscle homeostasis. Reynolds and colleagues showed in 2021 that MOTS-c reversed age-dependent physical decline in old mice. The effects parallel exercise adaptations, but no human clinical trial has confirmed these findings in people.

What does SS-31 do to mitochondria?

SS-31 (elamipretide) is a synthetic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. Cardiolipin anchors the electron transport chain complexes into functional supercomplexes. By stabilizing cardiolipin, SS-31 restores electron transport efficiency, reduces ROS production, and improves ATP synthesis. In aged mice, 8 weeks of treatment reversed oxidative protein damage in the heart.

Do mitochondrial peptides decline with age?

Circulating levels of both MOTS-c and humanin decrease with age. Cobb and colleagues measured these peptides across age groups in 2016 and found that the decline correlated with increasing insulin resistance and inflammatory markers. This creates a situation where protective peptide signals diminish at the same time mitochondrial damage accelerates.

Is elamipretide approved for any condition?

Elamipretide (SS-31) is not FDA-approved for any condition as of early 2026. It advanced into clinical trials for Barth syndrome, heart failure with preserved ejection fraction, and primary mitochondrial myopathy. Some trials showed improvements in specific endpoints, but pivotal heart failure trials did not meet their primary outcomes. Development continues for certain rare mitochondrial diseases.

Can peptides reverse mitochondrial aging in humans?

No human clinical trial has tested whether MOTS-c, humanin, or SS-31 can reverse mitochondrial aging. All aging-specific evidence comes from animal models, where results have been consistent and reproducible. SS-31's mixed results in human disease trials suggest that translating preclinical mitochondrial benefits into measurable clinical improvements is more complex than animal data implies.